IL-SKYWORKS-AERONAUTICS
24.6.2021 14:17:11 CEST | Business Wire | Press release
Today, Skyworks Aeronautics (“Skyworks”) announces the order of 100 eGyro™ electrically powered vertical take-off and landing (eVTOL) aircraft from a consortium of Mint Air (“Mint”) and Mobius.energy Corp (“Mobius”) with options for an additional 100 aircraft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005323/en/
“A consortium led by Mint Air is committed to bringing safe, efficient, and cost-effective electric aircraft solutions to South Korea and we are absolutely thrilled they have selected our eGyro as their aircraft of choice to initiate operation of the leading eVTOL service in Korea. We look forward to performing our first public demonstrations of the eGyro in Korea and to launching the eGyro Urban Air Mobility (UAM) platform in the Korean market,” said John Michel, Co-Founder & Executive Director of Skyworks.
“We are pleased to announce the Skyworks eGyro as the launch UAM platform for Mint Air. The fundamental safety and performance advantages of the eGyro will enable Mint Air to accelerate the adoption of intra and inter-city passenger transport in Korea,” said Eugene Choi, Chief Executive Officer of Mint Air.
The consortium led by Mint Air and Skyworks signed a Letter of Intent (LOI) for exclusive partnership in South Korea. The consortium will collaborate with Skyworks to develop a pilot training program and maintenance and repair capability in Korea for efficient operation of eGyro fleet.
The eGyro will leverage Mobius’ novel battery module architecture and low total cost of ownership providing power-as-a-service business model. “The high energy density, unmatched power boost, and outstanding thermal management of the Mobius battery modules support our efforts to produce an aircraft with best-in-class range and performance. We are excited to be the UAM launch platform for the Mobius battery module and service”, said Don Woodbury, Skyworks’ Co-Founder & Chief Technology Advisor.
Jongwon “JP” Park, Chief Strategy Officer and Co-Founder of Mobius said, “Mobius’ is building a global aviation battery alliance and our partnership with Skyworks to bring the eGyro to the Korean market marks an important milestone. Skyworks is the first of many customers who recognized the performance and safety of Mobius’ battery.”
About Mint Air
Mint Air is a startup company in stealth mode until now building an Advanced Air Mobility Service in South Korea. Mint Air’s approach is to facilitate an ecosystem of partners to accelerate the adoption of electric flight in Korea. A former global engineering part manufacturing company, Mint Air will take advantage of its global business experience and network to accelerate the development of the Urban Air Mobility ecosystem in Asia-Pacific markets. Beginning with air taxi operation, Mint Air aspires to become a global electric aircraft manufacturing company building electric aircraft supply chain, developing critical part manufacturing capability, and eventually assembling eGyro in Korea. For more information about the company, visit www.mintair.kr
About Mobius
Mobius.energy is developing safe, light, and energy-efficient novel battery module architecture. The module’s high discharge rate provides on-demand power boost needed during the take-off of electric aircraft at 7C which can last over 6 minutes. Its equally high charge rate enables fast charging in less than 10 minutes. Its light, simple, and compact design enables easy maintenance, on-site swapping, and cost-effective re-use and recycling. Mobius’ goal is to build battery subscription, maintenance, and salvage service including the second life repurpose and the end-of-life recycling of batteries to enable circular economy and thereby contribute to decarbonization of the aviation industry. For more information about the company, visit www.mobius.energy
About Skyworks Aeronautics
Skyworks Aeronautics is the world leader in the science and technology of gyronautics, focusing on the design and development of high-performance gyroplanes. Skyworks gyroplanes provide more affordable, safer, and higher performance alternatives for runway-independent aircraft.
Skyworks has more than 40 patents with several more underway, all obtained in an effort to radically change not only the way gyroplanes are perceived, but also the way they are utilized. From mass personnel transportation, agriculture, defense, and border protection to changing the economies of developing nations, Skyworks' goal is to change the nature of vertical flight. For more information about the company, its products, and individual members of the Skyworks team, visit www.skyworks-aero.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005323/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
